$229.48
2.83% today
NYSE, Sep 30, 06:45 pm CET
ISIN
US00287Y1091
Symbol
ABBV

AbbVie Stock price

$223.16
+12.76 6.06% 1M
+13.64 6.51% 6M
+45.46 25.58% YTD
+25.68 13.00% 1Y
+80.44 56.36% 3Y
+136.27 156.83% 5Y
+170.37 322.73% 10Y
+188.16 537.60% 20Y
NYSE, Closing price Mon, Sep 29 2025
+2.55 1.16%
ISIN
US00287Y1091
Symbol
ABBV
Industry

Key metrics

Basic
Market capitalization
$394.2b
Enterprise Value
$458.2b
Net debt
$64.0b
Cash
$6.5b
Shares outstanding
1.8b
Valuation (TTM | estimate)
P/E
106.3 | 18.2
P/S
6.8 | 6.4
EV/Sales
7.9 | 7.4
EV/FCF
25.1
P/B
negative
Dividends
DPS
$6.29
Yield 1Y | 5Y
2.8% | 4.2%
Growth 1Y | 5Y
5.0% | 7.5%
Payout 1Y | 3Y
263.2% | 153.2%
Increased
13 Years
Financials (TTM | estimate)
Revenue
$58.3b | $61.9b
EBITDA
$26.5b | $29.0b
EBIT
$18.2b | $27.7b
Net Income
$3.7b | $21.7b
Free Cash Flow
$18.2b
Growth (TTM | estimate)
Revenue
6.1% | 9.9%
EBITDA
8.0% | 16.6%
EBIT
13.8% | 68.1%
Net Income
-29.7% | 411.2%
Free Cash Flow
2.6%
Margin (TTM | estimate)
Gross
70.9%
EBITDA
45.5% | 46.9%
EBIT
31.3%
Net
6.4% | 35.0%
Free Cash Flow
31.3%
Financial Health
Equity Ratio
2.5%
Return on Equity
127.5%
ROCE
18.7%
ROIC
-
Debt/Equity
-385.1
More
EPS
$2.1
FCF per Share
$10.3
Short interest
0.9%
Employees
55k
Rev per Employee
$1.0m
Show more

Is AbbVie a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

AbbVie Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a AbbVie forecast:

26x Buy
70%
11x Hold
30%

Analyst Opinions

37 Analysts have issued a AbbVie forecast:

Buy
70%
Hold
30%

Financial data from AbbVie

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
58,328 58,328
6% 6%
100%
- Direct Costs 16,956 16,956
8% 8%
29%
41,372 41,372
13% 13%
71%
- Selling and Administrative Expenses 14,562 14,562
11% 11%
25%
- Research and Development Expense 8,602 8,602
14% 14%
15%
26,509 26,509
8% 8%
45%
- Depreciation and Amortization 8,270 8,270
3% 3%
14%
EBIT (Operating Income) EBIT 18,239 18,239
14% 14%
31%
Net Profit 3,723 3,723
30% 30%
6%

In millions USD.

Don't miss a Thing! We will send you all news about AbbVie directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AbbVie Stock News

Neutral
PRNewsWire
about 5 hours ago
– BLA based on data from the global Phase 1/2 CADENZA trial NORTH CHICAGO, Ill. , Sept. 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced submission of a new Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval of investigational Pivekimab sunirine (PVEK) for treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Neutral
GlobeNewsWire
about 18 hours ago
Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.
Neutral
PRNewsWire
one day ago
New state-of-the-art active pharmaceutical ingredient (API) facility will manufacture immunology, oncology and neuroscience medicines Facility expected to be fully operational and serving patients by 2027 Milestone marks progress on  AbbVie's long-term commitment to U.S. manufacturing NORTH CHICAGO, Ill. , Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construct...
More AbbVie News

Company Profile

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Head office United States
CEO Robert Michael
Employees 55,000
Founded 2011
Website www.abbvie.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today